SpringWorks Therapeutics, Inc. – NASDAQ:SWTX
SpringWorks Therapeutics stock price today
$46.98
+10.62
+29.24%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
SpringWorks Therapeutics stock price monthly change
-12.28%
month
SpringWorks Therapeutics stock price quarterly change
-12.28%
quarter
SpringWorks Therapeutics stock price yearly change
-1.86%
year
SpringWorks Therapeutics key metrics
Market Cap | 2.65B |
Enterprise value | 1.23B |
P/E | -4.67 |
EV/Sales | 200.71 |
EV/EBITDA | -4.48 |
Price/Sales | 210.83 |
Price/Book | 2.32 |
PEG ratio | 0.15 |
EPS | -4.98 |
Revenue | 37.86M |
EBITDA | -357.48M |
Income | -339.06M |
Revenue Q/Q | 278.00% |
Revenue Y/Y | 210.53% |
Profit margin | -4513.05% |
Oper. margin | -4566.03% |
Gross margin | 5.66% |
EBIT margin | -4566.03% |
EBITDA margin | -944.05% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSpringWorks Therapeutics stock price history
SpringWorks Therapeutics stock forecast
SpringWorks Therapeutics financial statements
| Jun 2023 | 5.82M | -77.92M | -1337.08% |
|---|---|---|---|
| Sep 2023 | 5.58M | -79.43M | -1422.07% |
| Dec 2023 | 5.44M | -94.32M | -1731.63% |
| Mar 2024 | 21.00M | -87.38M | -416% |
| Mar 2024 | 21.00M | -87.38M | -416% |
|---|---|---|---|
| Sep 2025 | 70.5M | -77.16M | -109.45% |
| Oct 2025 | 95.2M | -64.17M | -67.41% |
| Dec 2025 | 118.2M | -51.63M | -43.69% |
Analysts Price target
Financials & Ratios estimates
| 2023-08-02 | -1.25 | -1.25 |
|---|
| Jun 2023 | 517329000 | 65.88M | 12.74% |
|---|---|---|---|
| Sep 2023 | 467654000 | 72.75M | 15.56% |
| Dec 2023 | 725788000 | 99.56M | 13.72% |
| Mar 2024 | 656832000 | 89.39M | 13.61% |
| Jun 2023 | -47.81M | 60.75M | -342K |
|---|---|---|---|
| Sep 2023 | -50.46M | 34.59M | -242K |
| Dec 2023 | -62.70M | -159.20M | 299.07M |
| Mar 2024 | -78.93M | 21.46M | -552K |
SpringWorks Therapeutics alternative data
| Aug 2023 | 227 |
|---|---|
| Sep 2023 | 227 |
| Oct 2023 | 227 |
| Nov 2023 | 227 |
| Dec 2023 | 227 |
| Jan 2024 | 227 |
| Feb 2024 | 227 |
| Mar 2024 | 305 |
| Apr 2024 | 305 |
| May 2024 | 305 |
| Jun 2024 | 305 |
| Jul 2024 | 305 |
SpringWorks Therapeutics other data
100.00%
0.00%
of SWTX is owned by hedge funds
137
+0
58.99M
+4.22M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 49237 |
| Jun 2024 | 0 | 73648 |
| Sep 2024 | 0 | 69000 |
| Dec 2024 | 0 | 69000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | EDRIS BADREDDIN officer: Chief Op.. | Common Stock | 11,966 | $41.78 | $499,939 | ||
Sale | EDRIS BADREDDIN officer: Chief Op.. | Common Stock | 8,034 | $42.25 | $339,396 | ||
Sale | ISLAM SAQIB director, officer.. | Common Stock | 45,011 | $41.33 | $1,860,440 | ||
Sale | ISLAM SAQIB director, officer.. | Common Stock | 3,989 | $41.85 | $166,936 | ||
Sale | ISLAM SAQIB director, officer.. | Common Stock | 32,400 | $40.1 | $1,299,240 | ||
Sale | ISLAM SAQIB director, officer.. | Common Stock | 9,908 | $41.1 | $407,258 | ||
Sale | ISLAM SAQIB director, officer.. | Common Stock | 6,692 | $42.07 | $281,553 | ||
Sale | EDRIS BADREDDIN officer: Chief Op.. | Common Stock | 12,300 | $40.12 | $493,415 | ||
Sale | EDRIS BADREDDIN officer: Chief Op.. | Common Stock | 4,620 | $41.12 | $189,956 | ||
Sale | EDRIS BADREDDIN officer: Chief Op.. | Common Stock | 3,080 | $42.08 | $129,591 |
| Quarter | Transcript |
|---|---|
| Q1 2024 5 May 2024 | Q1 2024 Earnings Call Transcript |
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
Immunome: AL102 And Other Established Protein Targets Could Drive Value
Celebrating Seeking Alpha's New Analysts - November 2023 Edition
SpringWorks Therapeutics: How A Likely FDA Approval Can Kickstart The Stock's Repricing Potential
SpringWorks Therapeutics: FDA Decision Date Ahead
SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline
SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
Allogene: Speculative CAR T Biotech With Big Potential In Oncology
-
What's the price of SpringWorks Therapeutics stock today?
One share of SpringWorks Therapeutics stock can currently be purchased for approximately $46.98.
-
When is SpringWorks Therapeutics's next earnings date?
Unfortunately, SpringWorks Therapeutics's (SWTX) next earnings date is currently unknown.
-
Does SpringWorks Therapeutics pay dividends?
No, SpringWorks Therapeutics does not pay dividends.
-
How much money does SpringWorks Therapeutics make?
SpringWorks Therapeutics has a market capitalization of 2.65B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 11.39% to 5.45M US dollars. SpringWorks Therapeutics made a loss 325.1M US dollars in net income (profit) last year or -$1.25 on an earnings per share basis.
-
What is SpringWorks Therapeutics's stock symbol?
SpringWorks Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SWTX".
-
What is SpringWorks Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of SpringWorks Therapeutics?
Shares of SpringWorks Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are SpringWorks Therapeutics's key executives?
SpringWorks Therapeutics's management team includes the following people:
- Mr. Saqib Islam Chief Executive Officer & Director(age: 55, pay: $946,310)
- Dr. L. Mary Smith PH.D. Chief Devel. Officer(age: 58, pay: $655,200)
- Dr. Badreddin Edris Ph.D. Chief Operating Officer(age: 38, pay: $655,200)
- Mr. Francis I. Perier Jr., M.B.A. Chief Financial Officer(age: 65, pay: $648,960)
- Mr. Herschel S. Weinstein J.D. Gen. Counsel & Sec.(age: 69, pay: $568,640)
- Mr. Daniel Pichl Chief People Officer(age: 42, pay: $428,510)
-
How many employees does SpringWorks Therapeutics have?
As Jul 2024, SpringWorks Therapeutics employs 305 workers.
-
When SpringWorks Therapeutics went public?
SpringWorks Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 13 Sep 2019.
-
What is SpringWorks Therapeutics's official website?
The official website for SpringWorks Therapeutics is springworkstx.com.
-
Where are SpringWorks Therapeutics's headquarters?
SpringWorks Therapeutics is headquartered at 100 Washington Boulevard, Stamford, CT.
-
How can i contact SpringWorks Therapeutics?
SpringWorks Therapeutics's mailing address is 100 Washington Boulevard, Stamford, CT and company can be reached via phone at +20 3 8839490.
SpringWorks Therapeutics company profile:
SpringWorks Therapeutics, Inc.
springworkstx.comExchange:
NASDAQ
Full time employees:
305
Industry:
Biotechnology
Sector:
Healthcare
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
100 Washington Boulevard
Stamford, CT 06902
Stamford, CT 06902
CIK: 0001773427
ISIN: US85205L1070
CUSIP: 85205L107
